This is a genetic condition that affects how your body processes fats (lipids) in your blood. It causes your levels of cholesterol and/or triglycerides to be higher than normal. It's called 'combined' because it can affect different types of fats in the blood, and 'familial' means it runs in families, often being inherited.
Every report comes from a Lived member, sent anonymously.
Have you tried Crestor (Rosuvastatin) for Familial Combined Hyperlipidemia?
Familial combined hyperlipidemia (FCHL) is an inherited tendency to have too much fat in the blood, usually raised cholesterol, raised triglycerides or both. It is the most common inherited disorder of blood fats, yet it often goes undiagnosed, because high levels cause no symptoms until they have already damaged the arteries. The condition matters because these fats help build plaque inside artery walls, a process called atherosclerosis. Over years, that narrowing makes a heart attack or stroke more likely, and at a younger age than usual. People with FCHL are also more likely to develop type 2 diabetes and fatty liver disease (now often called steatotic liver disease). A distinctive feature is that the pattern can shift. In one family, one person may have mainly high cholesterol, another mainly high triglycerides and another both. The same person's results can also change from year to year. The word "combined" describes this family-wide picture rather than any single blood test.
FCHL runs in families, but it is not caused by one gene. Researchers now understand it as polygenic: many common gene variants, each with a small effect and many of them pushing triglycerides up, add together to create the tendency. The exact mix can differ from one family to another, so there is no single genetic test that settles the diagnosis. The inherited tendency works together with everyday factors. In FCHL the liver tends to release too many triglyceride-carrying particles called very low-density lipoprotein (VLDL), and this is closely tied to insulin resistance, meaning the body responds less well to its own insulin. Weight gain, fat build-up in the liver, diabetes, alcohol and an underactive thyroid (hypothyroidism) can all push levels higher. Changes in weight and liver fat are a main reason triglycerides, and with them the whole lipid pattern, rise and fall over time. Having a parent or sibling with FCHL, or with heart disease at a young age, makes the condition more likely. It does not fix a person's outcome, since treatment changes the course considerably.
There is no single test for FCHL. The diagnosis rests on blood test results read together with family history, after other causes have been ruled out. The starting point is a lipid panel, reported in milligrams per deciliter (mg/dL). Triglycerides below 150 are normal, 150 to 199 is borderline high, 200 to 499 is high and 500 or more is very high. For most adults, LDL cholesterol (the main cholesterol in artery plaque) is considered healthy below 100. High-density lipoprotein (HDL) is the "good" cholesterol, and non-HDL cholesterol is total cholesterol minus HDL; it counts the cholesterol in every plaque-forming particle, and for adults below 130 is the general healthy level. Clinicians often add apolipoprotein B (apoB), a measure of how many plaque-forming particles are circulating. This matters in FCHL because LDL cholesterol can look only mildly raised while apoB is high, so LDL alone underestimates risk when triglycerides are elevated. An apoB of 130 mg/dL or higher, especially with persistently high triglycerides, signals high lifetime risk. Because the pattern fluctuates, a clinician looks for repeated abnormal results, different lipid patterns among relatives and a family history of early heart disease. Tests of thyroid, kidney and liver function and of blood sugar check for conditions that raise blood fats on their own. A very high LDL on its own points instead toward familial hypercholesterolemia, a different inherited disorder.
Treatment aims to prevent heart attacks and strokes, not only to bring numbers into range. Lifestyle change is the foundation and carries particular weight in FCHL, because body weight, liver fat and insulin resistance drive much of the swing in triglycerides. Eating less saturated fat and refined sugar, limiting alcohol, losing weight where appropriate, staying physically active and not smoking can lower triglycerides and also reduce the chance of developing type 2 diabetes. A dietitian can help turn this into a practical eating plan. Most people with FCHL also need medicine, because the inherited tendency does not go away. Statins, such as atorvastatin (Lipitor) or rosuvastatin (Crestor), are the cornerstone. They are the most effective medicines for lowering LDL cholesterol, and higher-intensity doses typically cut it by half or more. Muscle aches are the side effect people most often notice; most people who have them can still take a statin after switching to another one or changing the dose. Statins slightly raise the chance of diabetes in people already prone to it, which guidelines do not consider a reason to stop. If levels stay above goal, other medicines can be added. Ezetimibe (Zetia) is a daily pill that lowers LDL cholesterol further, and evolocumab (Repatha), an injection from a group called PCSK9 inhibitors after the protein they block, lowers it substantially. Fibrates such as fenofibrate lower triglycerides, but trials have not shown that adding one to a statin prevents more heart problems, so they are used selectively. Progress is judged by non-HDL cholesterol or apoB as well as LDL.
FCHL is lifelong. Raised levels often first appear in the teens or in a person's 20s and 30s, and the tendency stays, although the pattern can drift with weight, diet, alcohol and diabetes control. Most people feel nothing from the numbers themselves, so the benefit of treatment is preventive: less plaque building up over decades. In daily life this usually means a daily medicine, steady eating and activity habits, and repeat lipid tests after treatment starts or changes and then periodically. Because type 2 diabetes and fatty liver disease are more common with FCHL, follow-up often includes blood sugar checks and sometimes liver tests or imaging. Blood pressure and smoking matter too, since they add to the same artery damage. Outlook depends a great deal on how early the condition is found and how consistently it is treated. Even with modern treatment, people with FCHL remain at higher cardiovascular risk than average, and standard risk calculators can underestimate it, which is one reason clinicians may treat more intensively than the numbers alone suggest. Telling close relatives about the diagnosis gives them a chance to be tested early.
Ask for a lipid panel if a parent, sibling or child has FCHL, very high cholesterol or triglycerides, or a heart attack or stroke at a young age; children in such families can be tested from as early as age 2. Arrange a visit if follow-up results stay above your goal, if side effects make it hard to keep taking treatment, or if you notice calf cramping when walking or sores on the toes that do not heal, which can signal narrowed leg arteries. Call 911 for chest pain or pressure lasting more than a few minutes or coming back, especially with shortness of breath, a cold sweat or discomfort spreading to the arm, back or jaw. Also call 911 for sudden face drooping, weakness of an arm or leg, or trouble speaking. These can be signs of a heart attack or stroke, which FCHL makes more likely at a younger age, and fast treatment limits the damage.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Familial Combined Hyperlipidemia is like, what's helped you, or ask the community a question.